StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck AstraZeneca by Year

AstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current payables / liabilities to partner ($M) ($M)

Merck AstraZeneca: $6M in FY2025, down 99.2% from a year earlier. That is the lowest of the 8 years on record here.

Latest, FY2025
6
Period ended Dec 31, 2025
Change on a year earlier
-99.2%
713 in FY2024
History
8 years
Since FY2017
Sources
8
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-Q (filed 2026-08-07) ↗

Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAstraZeneca (Lynparza & Koselugo Oncology Alliance) — Current payables / liabilities to partner ($M) ($M)Year on yearSource
FY2025Dec 31, 20256-99.2%Form 10-Q (filed 2026-08-07) ↗
FY2024Dec 31, 2024713+178.5%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 2023256+108.1%Form 10-K (filed 2025-02-25) ↗
FY2022Dec 31, 2022123-70.4%Form 10-K (filed 2024-02-26) ↗
FY2021Dec 31, 2021415-1.9%Form 10-K (filed 2023-02-24) ↗
FY2020Dec 31, 2020423-26.7%Form 10-K (filed 2022-02-25) ↗
FY2019Dec 31, 2019577–Form 10-Q (filed 2020-11-05) ↗
FY2017Dec 31, 2017100–Form 10-Q (filed 2018-05-08) ↗

Cite this data

StockData. (2026). Merck AstraZeneca ($M), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-astrazeneca-ap-cur

See every metric in the Merck KPI table. Data updated Oct 26, 2026.